Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
JD.com shares fell 9% after weak retail growth overshadowed a Q2 earnings beat. The setup shifts toward execution risk: strong reported revenue growth and profitability are being discounted against softer retail momentum.
Zentalis Pharmaceuticals priced an underwritten offering of 23,000,000 shares at $3.50 each, targeting approximately $80.5 million in gross proceeds. The financing extends the runway for azenosertib development but puts near-term pressure on ZNTL through substantial equity issuance and dilution.
US annual inflation eased to 3.4% in July as food-price growth slowed, while housing continued to keep overall prices elevated. The softer reading reduces near-term inflation pressure, but housing leaves the path for monetary-policy easing less clear.
The US will impose tariffs of up to 100% on Chinese unmanned aircraft and their components, according to the Financial Times. The policy raises costs and supply-chain uncertainty for drone manufacturers and users while potentially accelerating demand for non-Chinese alternatives.
The SEC canceled a scheduled meeting on its long-awaited Reg Crypto proposal and postponed it without setting a new date. The delay extends regulatory uncertainty for the crypto market, but the sparse disclosure does not establish a directional read on any single asset.
The US sold 30-year bonds at their highest borrowing costs since 2001 as yields jumped on concerns about mounting public debt and persistently high inflation. The result reinforces pressure on long-duration assets and keeps fiscal and inflation risk at the center of the rates outlook.
Tether says KPMG U.S. completed a financial audit of the reserves behind its $180 billion USDT stablecoin, including a count of its gold bars. The report could strengthen transparency around the largest dollar stablecoin, but without the audit’s detailed findings or a listed equity directly tied to Tether, the immediate market trade remains limited.
The U.S. will allow some private firms to conduct cyberattacks, reversing decades of policy that prohibited private-sector “hack back” operations. The order creates a major regulatory opening for offensive cybersecurity providers, but also raises legal, attribution and escalation risks across the sector.
Japan’s producer-price inflation missed expectations in July but reached a three-and-a-half-year peak. The combination points to firmer upstream price pressure without a clean upside surprise, leaving the policy and yen implications mixed.
Nvidia is working with Wall Street groups on a funding package of up to $500bn for AI infrastructure, positioning the chipmaker as a central financier as well as a supplier. The structure could expand demand for Nvidia systems, but it also ties future growth more closely to financing capacity and AI infrastructure credit risk.
Super Micro’s latest forecast is exceeding expectations after the company signaled an improved profitability trajectory, sending the stock higher. The setup shifts toward execution risk: strong growth is now paired with thin reported margins, leaving less room for a miss in the next earnings cycle.
Home Depot CEO Ted Decker is taking medical leave and is expected to return in a few months, with two executives appointed to oversee his duties. The temporary leadership handoff adds execution risk to a company generating $164.7B of revenue but does not yet signal a permanent management change.
BioMar raised its 2026 revenue guidance to DKK 17-18 billion from DKK 16-17 billion and EBIT guidance to DKK 1,200-1,300 million from DKK 1,100-1,200 million. The upgrade is clearly positive for BioMar, but with no ticker, consensus, valuation, or price-reaction data supplied, the trade read is limited to the guidance reset.
A benign Consumer Price Index reading would reduce pressure on officials to raise borrowing costs at the September meeting, while a hotter report could revive the case for tighter policy. The setup leaves rate-sensitive assets driven by the inflation surprise rather than by a clear directional signal in advance.
AstraZeneca’s potential $400bn agreement unravelled after investors mounted opposition, according to the Financial Times. The revolt puts deal execution and capital-allocation risk at the center of the AZN setup, even as the company’s latest enrichment shows $58.7B of revenue growing 8.6% YoY.